Two Sigma Advisers LP Reduces Position in Hologic, Inc. (NASDAQ:HOLX)

Two Sigma Advisers LP lessened its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 3.3% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,878,620 shares of the medical equipment provider’s stock after selling 64,100 shares during the quarter. Two Sigma Advisers LP owned about 0.73% of Hologic worth $107,081,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in HOLX. ArrowMark Colorado Holdings LLC purchased a new position in Hologic during the 2nd quarter worth approximately $88,797,000. Deerfield Management Company L.P. Series C acquired a new stake in Hologic during the 2nd quarter worth approximately $78,101,000. Point72 Asset Management L.P. lifted its position in Hologic by 1,409.8% during the 2nd quarter. Point72 Asset Management L.P. now owns 1,182,513 shares of the medical equipment provider’s stock worth $67,403,000 after acquiring an additional 1,104,193 shares during the period. MUFG Securities EMEA plc lifted its position in Hologic by 1,199.9% during the 2nd quarter. MUFG Securities EMEA plc now owns 942,000 shares of the medical equipment provider’s stock worth $53,694,000 after acquiring an additional 869,531 shares during the period. Finally, Avidity Partners Management LP acquired a new stake in Hologic during the 2nd quarter worth approximately $46,580,000. Hedge funds and other institutional investors own 93.69% of the company’s stock.

In other Hologic news, insider Peter J. Valenti III sold 10,493 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $54.07, for a total value of $567,356.51. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin Jordan Cohn sold 4,924 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $71.24, for a total transaction of $350,785.76. The disclosure for this sale can be found here. Corporate insiders own 1.00% of the company’s stock.

HOLX stock traded down $0.12 during trading on Wednesday, reaching $60.77. 1,547,573 shares of the company were exchanged, compared to its average volume of 2,659,033. The company has a 50-day moving average of $64.67 and a two-hundred day moving average of $52.66. The company has a market capitalization of $15.74 billion, a price-to-earnings ratio of 24.64, a P/E/G ratio of 1.33 and a beta of 1.40. Hologic, Inc. has a twelve month low of $26.49 and a twelve month high of $73.63. The company has a debt-to-equity ratio of 1.22, a current ratio of 1.47 and a quick ratio of 1.17.

Hologic (NASDAQ:HOLX) last released its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.38 by $0.37. The business had revenue of $822.90 million during the quarter, compared to analysts’ expectations of $622.96 million. Hologic had a net margin of 20.03% and a return on equity of 31.40%. The firm’s quarterly revenue was down 3.4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.63 EPS. On average, analysts forecast that Hologic, Inc. will post 3.01 EPS for the current year.

A number of research firms have weighed in on HOLX. Morgan Stanley increased their price objective on Hologic from $55.00 to $68.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Monday, July 27th. Zacks Investment Research raised Hologic from a “hold” rating to a “strong-buy” rating and set a $82.00 price objective for the company in a research report on Tuesday, August 4th. Wells Fargo & Company raised their price target on Hologic from $63.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Finally, Citigroup raised their price target on Hologic from $63.00 to $85.00 and gave the company a “buy” rating in a report on Thursday, July 30th. Six analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $67.60.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Featured Story: Elliott Wave Theory

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit